Format

Send to

Choose Destination
See comment in PubMed Commons below
Semergen. 2014 Mar;40(2):80-8. doi: 10.1016/j.semerg.2012.12.001. Epub 2013 Feb 4.

[Cardiovascular effects and safety of glucose-lowering drugs: current situation].

[Article in Spanish]

Author information

1
Servicio de Endocrinología, Hospital Son Llàtzer, Palma de Mallorca, España. Electronic address: lmasmiquel@hsll.es.

Abstract

Diabetes mellitus is an independent cardiovascular risk factor. Therefore, in addition to normalising blood glucose, the aim of the treatment for diabetes mellitus should be to prevent cardiovascular complications. However, the evidence available on the cardio-protective role of the different glucose-lowering drugs is scarce and poor, particularly as regards with the risk of major cardiovascular events. In this context, the regulatory agencies have modified the regulations for the approval of glucose-lowering drugs, now requiring to demonstrate the glucose-lowering effect together with a robust assessment of the cardiovascular safety. The aim of this work is to review the cardiovascular effects of the different glucose-lowering drugs, focusing on their impact on the risk of major cardiovascular events.

KEYWORDS:

Anti-diabetics; Antidiabéticos; Cardiovascular risk; Diabetes mellitus; Eventos cardiovasculares mayores; Glucose-lowering drugs; Hipoglucemiantes; Major cardiovascular events; Riesgo cardiovascular

PMID:
24655910
DOI:
10.1016/j.semerg.2012.12.001
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center